scholarly journals Stereoelectronic Features of a Complex Ketene Dimerization Reaction

Molecules ◽  
2021 ◽  
Vol 27 (1) ◽  
pp. 66
Author(s):  
Robert D. Barrows ◽  
Mark J. Dresel ◽  
Thomas J. Emge ◽  
Paul R. Rablen ◽  
Spencer Knapp

The amidation reaction of a tetrahydroisoquinolin-1-one-4-carboxylic acid is a key step in the multi-kilogram-scale preparation of the antimalarial drug SJ733, now in phase 2 clinical trials. In the course of investigating THIQ carboxamidations, we found that propanephosphonic acid anhydride (T3P) is an effective reagent, although the yield and byproducts vary with the nature and quantity of the base. As a control, the T3P reaction of a 3-(2-thienyl) THIQ was performed in the absence of the amine, and the products were characterized: among them are three dimeric allenes and two dimeric lactones. A nucleophile-promoted ketene dimerization process subject to subtle steric and stereoelectronic effects accounts for their formation. Two novel monomeric products, a decarboxylated isoquinolone and a purple, fused aryl ketone, were also isolated, and mechanisms for their formation from the ketene intermediate are proposed.

2005 ◽  
Vol 7 (4) ◽  
pp. 425-434 ◽  
Author(s):  
Susan M. Chang ◽  
Sharon L. Reynolds ◽  
Nicholas Butowski ◽  
Kathleen R. Lamborn ◽  
Jan C. Buckner ◽  
...  

2010 ◽  
Vol 52 (10) ◽  
pp. 875-881 ◽  
Author(s):  
I. J. van den Elskamp ◽  
B. Boden ◽  
V. Dattola ◽  
D. L. Knol ◽  
M. Filippi ◽  
...  

Blood ◽  
2003 ◽  
Vol 102 (2) ◽  
pp. 442-448 ◽  
Author(s):  
Elihu H. Estey ◽  
Peter F. Thall

AbstractConventional phase 2 clinical trials are typically single-arm experiments, with outcome characterized by one binary “response” variable. Clinical investigators are poorly served by such conventional methodology. We contend that phase 2 trials are inherently comparative, with the results of the comparison determining whether to conduct a subsequent phase 3 trial. When different treatments are studied in separate single-arm trials, actual differences between response rates associated with the treatments, “treatment effects,” are confounded with differences between the trials, “trial effects.” Thus, it is impossible to estimate either effect separately. Consequently, when the results of separate single-arm trials of different treatments are compared, an apparent treatment difference may be due to a trial effect. Conversely, the apparent absence of a treatment effect may be due to an actual treatment effect being cancelled out by a trial effect. Because selection involves comparison, single-arm phase 2 trials thus fail to provide a reliable means for selecting which therapies to investigate in phase 3. Moreover, reducing complex clinical phenomena, including both adverse and desirable events, to a single outcome wastes important information. Consequently, conventional phase 2 designs are inefficient and unreliable. Given the limited number of patients available for phase 2 trials and the increasing number of new therapies that must be evaluated, it is critically important to conduct these trials efficiently. These concerns motivated the development of a general paradigm for randomized selection trials evaluating several therapies based on multiple outcomes. Three illustrative applications of trials using this approach are presented.


2014 ◽  
Vol 209 (12) ◽  
pp. 1949-1954 ◽  
Author(s):  
L. F. Shubitz ◽  
H. T. Trinh ◽  
R. H. Perrill ◽  
C. M. Thompson ◽  
N. J. Hanan ◽  
...  

2011 ◽  
Vol 45 (3) ◽  
pp. 315-330
Author(s):  
Xiaoyin Frank Fan ◽  
Chris A. Assaid ◽  
Yang Joy Ge ◽  
Tony W. H. Ho

Sign in / Sign up

Export Citation Format

Share Document